Valuation: Viatris Inc.

Capitalization 20.23B 17.27B 15.83B 14.96B 27.71B 1,936B 27.85B 188B 73.37B 919B 75.9B 74.31B 3,193B P/E ratio 2026 *
66.8x
P/E ratio 2027 * 33.5x
Enterprise value 32.32B 27.6B 25.29B 23.91B 44.27B 3,093B 44.5B 301B 117B 1,468B 121B 119B 5,102B EV / Sales 2026 *
2.19x
EV / Sales 2027 * 2.07x
Free-Float
92.1%
Yield 2026 *
2.93%
Yield 2027 * 3%
1 day-0.46%
1 week+8.90%
Current month+16.27%
1 month+25.60%
3 months+10.15%
6 months+59.21%
Current year+39.52%
1 week 16.64
Extreme 16.635
17.53
1 month 13.67
Extreme 13.67
17.53
Current year 12.19
Extreme 12.19
17.53
1 year 8.19
Extreme 8.19
17.53
3 years 6.85
Extreme 6.85
17.53
5 years 6.85
Extreme 6.85
17.53
10 years 6.85
Extreme 6.85
50.4
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Administrative Officer - 19/08/2025
Director TitleAgeSince
Chairman 58 15/12/2023
Director/Board Member 70 16/11/2020
Director/Board Member 78 16/11/2020
Change 5d. change 1-year change 3-years change Capi.($)
+1.16%+8.90%+97.61%+87.18% 20.23B
+2.61%+2.91%+36.15%+133.81% 906B
+2.75%+2.58%+55.23%+43.31% 555B
+0.31%+1.69%+10.90%+41.69% 368B
-0.94%-2.05%+21.74%+10.73% 326B
+0.63%+3.98%+38.14%+15.37% 289B
+0.78%+1.00%+29.63%+26.23% 285B
+0.96%-0.10%+48.05%-3.15% 280B
+0.91%+2.12%-31.78%-49.10% 208B
+0.05%+1.61%+24.40%+44.43% 182B
Average +0.24%+1.86%+33.01%+35.05% 341.87B
Weighted average by Cap. +0.35%+1.29%+31.36%+51.11%

Financials

2026 *2027 *
Net sales 14.75B 12.6B 11.54B 10.91B 20.2B 1,412B 20.31B 137B 53.5B 670B 55.34B 54.18B 2,328B 15.04B 12.84B 11.77B 11.12B 20.6B 1,439B 20.71B 140B 54.55B 683B 56.43B 55.24B 2,374B
Net income 96.33M 82.27M 75.38M 71.26M 132M 9.22B 133M 898M 349M 4.38B 361M 354M 15.21B 404M 345M 316M 299M 554M 38.69B 557M 3.77B 1.47B 18.36B 1.52B 1.48B 63.81B
Net Debt 12.09B 10.32B 9.46B 8.94B 16.56B 1,157B 16.65B 113B 43.85B 549B 45.36B 44.41B 1,908B 10.88B 9.29B 8.51B 8.05B 14.9B 1,041B 14.98B 101B 39.47B 494B 40.83B 39.97B 1,718B
Logo Viatris Inc.
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
Employees
30,000
Date Price Change Volume
13/05/26 17.37 $ +1.16% 14,317,223
12/05/26 17.17 $ +1.48% 12,267,772
11/05/26 16.92 $ -1.46% 14,119,499
08/05/26 17.17 $ -1.27% 20,242,689
07/05/26 17.39 $ +9.03% 34,754,321
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
17.37USD
Average target price
17.50USD
Spread / Average Target
+0.75%

Quarterly revenue - Rate of surprise